| Nov 14 |
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 13 |
bluebird bio Q3 2024 Earnings Preview
|
| Nov 6 |
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
|
| Nov 5 |
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
|
| Oct 31 |
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies
|
| Oct 11 |
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
|
| Oct 10 |
7 children given bluebird's Skysona developed blood cancer: study
|
| Oct 10 |
Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials
|
| Oct 9 |
Top 10 most shorted stocks on Wall Street
|
